Evidence map›Paper›PMID 35028748›Full record

SynthesisEuropean radiology2022

Application of diffusion-weighted whole-body MRI for response monitoring in multiple myeloma after chemotherapy: a systematic review and meta-analysis.

Kaiwen Wang, Elsa Lee, Shedrack Kenis, Simon Hallam, Athar Haroon, Simon Wan, Neil Rabin, Antonio Rojas-Garcia, Anwar Padhani, Sola Adeleke

Abstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in European radiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Imaging of Multiple Myeloma: Present and Future.Journal of clinical medicine · 2024
    Review
  3. Review
  4. Article
  5. Progress of modern imaging modalities in multiple myeloma.International journal of hematology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 8 institutions in 1 country.

Kaiwen WangSchool of Clinical Medicine, The University of Cambridge, Cambridge, UK.
Elsa LeeGuy's, King's and St Thomas' School of Medicine, King's College London, London, UK.
Shedrack KenisEcholab Radiology and Laboratory Services, Benin, Nigeria.
Simon HallamDepartment of Haemato-oncology, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK.
Athar HaroonDepartment of Nuclear Medicine, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK.
Simon WanInstitute of Nuclear Medicine, UCL and UCL Hospitals, London, UK.
Neil RabinDepartment of Haemato-Oncology, Barts Health NHS Trust, London, UK.
Antonio Rojas-GarciaPublic Health Policy Evaluation Unit, School of Public Health, Imperial College London, London, UK.
Anwar PadhaniPaul Strickland Scanner Centre, Mount Vernon Hospital, Northwood, UK.
Sola AdelekeSchool of Cancer & Pharmaceutical Sciences, King's College London, Strand, London, WC2R 2LS, UK. sesola2003@gmail.com.ORCID http://orcid.org/0000-0002-4388-8754
St Bartholomew's Hospital · GBBarts Health NHS Trust · GBImperial College London · GBKing's College London · GBMount Vernon Hospital · GBSt Thomas' Hospital · GBUniversity College London · GBUniversity of Leeds · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveMyeloma Response Assessment and Diagnosis System recently published provides a framework for the standardised interpretation of DW-WBMRI in response assessment of multiple myeloma (MM) based on expert opinion. However, there is a lack of meta-analysis providing higher-level evidence to support the recommendations. In addition, some disagreement exists in the literature regarding the effect of timing and lesion subtypes on apparent diffusion coefficient (ADC) value changes post-treatment.

methodMedline, Cochrane and Embase were searched from inception to 20th July 2021, using terms reflecting multiple myeloma and DW-WBMRI. Using PRISMA reporting guidelines, data were extracted by two investigators. Quality was assessed by the Quality Assessment of Diagnostic Accuracy Studies-2 method.

resultsOf the 74 papers screened, 10 studies were included comprising 259 patients (127 males and 102 females) and 1744 reported lesions. Responders showed a significant absolute ADC change of 0.21×10

conclusionsThis meta-analysis supports the use of the DW-WBMRI as an imaging biomarker for response assessment. More evidence is needed to further characterise ADC changes by lesion subtypes over time. KEY POINTS: • In multiple myeloma patients who received chemotherapy, responders have a significant absolute increase in ADC values that is not seen in non-responders. • A 35% increase in ADC from baseline values is found to classify response post-induction chemotherapy which corroborates with expert opinion from the Myeloma Response Assessment and Diagnosis System. • More evidence is needed to further characterise ADC changes by lesion subtypes over time after induction of therapy.

Indexed as

Multiple MyelomaDiffusion Magnetic Resonance ImagingFemaleHumansInduction ChemotherapyMaleBiomarkersDiffusion magnetic resonance imagingMeta-analysisMultiple myeloma

Identifiers

PMID35028748
OpenAlexW4205483812

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.